At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
May 20, 2024 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
March 12, 2024 07:30 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
Arecor: Business Update
July 20, 2023 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
BUSINESS UPDATE
January 20, 2022 07:01 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
January 20, 2022 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP First patient dosed in potential...
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
November 01, 2021 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER...